Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
1.960
0.00 (0.00%)
Dec 20, 2024, 4:00 PM EST - Market closed
Immuron Employees
Immuron had 7 employees as of June 30, 2024. The number of employees increased by 1 or 16.67% compared to the previous year.
Employees
7
Change (1Y)
1
Growth (1Y)
16.67%
Revenue / Employee
$467,313
Profits / Employee
-$661,192
Market Cap
11.18M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 7 | 1 | 16.67% |
| Jun 30, 2023 | 6 | 1 | 20.00% |
| Jun 30, 2022 | 5 | -11 | -68.75% |
| Jun 30, 2014 | 16 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Lyra Therapeutics | 88 |
| Turnstone Biologics | 80 |
| BiomX | 71 |
| Jaguar Health | 49 |
| Apollomics | 45 |
| Sensei Biotherapeutics | 28 |
| Relmada Therapeutics | 20 |
| Talphera | 15 |
IMRN News
- 19 days ago - Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th - GlobeNewsWire
- 4 weeks ago - Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event - GlobeNewsWire
- 4 weeks ago - Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event - Accesswire
- 2 months ago - Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference - GlobeNewsWire
- 2 months ago - Immuron Travelan® continued strong sales growth - GlobeNewsWire
- 2 months ago - NMRC Reports Results for Campylobacter Controlled Human Infection Model Study - GlobeNewsWire
- 3 months ago - Traveler's Diarrhea Therapeutics Pipeline Market Report 2024 Featuring Immuron, Scandinavian Biopharma, and Sigmoid Pharma - GlobeNewsWire
- 3 months ago - Immuron Plans Phase 2 Trial for IMM-529 following FDA review - GlobeNewsWire